Human Patents (Class 435/366)
  • Patent number: 10287549
    Abstract: Provided is a muscle stem cell in vitro culture method. A muscle stem cell is cultivated in vitro by using a cell culture medium of a cell factor added with a blood cell or a conditioned medium of the blood cell. Also provided is a culture medium used in the muscle stem cell in vitro culture method and an application thereof.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: May 14, 2019
    Assignee: Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
    Inventors: Ping Hu, Xin Fu, Jun Xiao
  • Patent number: 10278993
    Abstract: A method for the treatment of acute stroke in a subject by administering to said subject an effective amount of a cell-based composition containing a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: May 7, 2019
    Assignee: Cytopeutics Sdn. Bhd.
    Inventors: Bernard Sze-Piaw Chin, Kong Yong Then, Soon Keng Cheong
  • Patent number: 10273459
    Abstract: The invention provides an automated system for producing induced pluripotent stem cells (iPSCs) from adult somatic cells. Further, the system is used for producing differentiated adult cells from stem cells. The invention system is useful for isolating somatic cells from tissue samples, producing iPSC lines from adult differentiated cells by reprogramming such cells, identifying the pluripotent reprogrammed adult cells among other cells, and expanding and screening the identified reprogrammed cells.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: April 30, 2019
    Assignee: New York Stem Cell Foundation
    Inventors: Scott Noggle, Kevin C. Eggan, Stephen Chang, Susan Solomon
  • Patent number: 10190097
    Abstract: The present invention provides a method of forming a fibromodulin (FMOD) reprogrammed (FReP) cell. The method comprises steps of treating a human cell with a cell culture medium comprising fibromodulin (FMOD) for a period ranging from a day to a month, and changing the cell culture medium regularly until a FMOD reprogrammed (FreP) cell forms; wherein the FreP cell expresses NANOG and does not form teratoma, and wherein the human cell is a fibroblastic cell.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 29, 2019
    Assignee: The Regents of the University of California
    Inventors: B. Chia Soo, Kang Ting, Zhong Zheng
  • Patent number: 10179152
    Abstract: Provided herein are methods of treatment comprising administering to a subject, e.g., a human subject, mononuclear cells from human placental perfusate and hematopoietic cells, and compositions comprising them, and their uses to establish chimerism, engraft tissue (e.g., blood), reduce the severity or duration of graft versus host disease, and treat or ameliorate symptoms of metabolic disorders and hematologic disorders, such as hematologic malignancies.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: January 15, 2019
    Assignee: Celularity, Inc.
    Inventors: Jodi P. Gurney, Xiaokui Zhang, Stacy Herb, Robert J. Hariri
  • Patent number: 10167449
    Abstract: An isolated human brown adipose tissue stem cell line. In one embodiment, the isolated human brown adipose tissue stem cell line expresses the markers CD9, SSEA4, CD44, CD90, CD166, CD73, but not CD14, CD34, CD45 or STRO-1. In another embodiment, the isolated human brown adipose tissue stem cell line expresses the genes UCP1, PPARGC1A, NRF1, FOXC2, CREB1, SIRT3, and WNT5A (REFX). In still another embodiment, the isolated human brown adipose tissue stem cell line is capable of differentiating into osteoblasts, chondrocytes, and adipocytes.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: January 1, 2019
    Assignee: BIORESTORATIVE THERAPIES, INC.
    Inventor: Francisco Javier Silva
  • Patent number: 10155927
    Abstract: This application relates to a method for differentiating pluripotent stem cells (PSCs) into cardiomyocytes. Moreover this application relates to a method for differentiating human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) into defined cardiomyocytes based on linked steps of chemically defined medium inductions.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: December 18, 2018
    Assignee: HOFFMANN-LA-ROCHE INC.
    Inventors: Mark Burcin, Sonja Schlicht
  • Patent number: 10150946
    Abstract: The present invention relates to a medium for storing, preserving, culturing, and/or differentiating stem cells. The medium employs a synthetic thermo-responsive copolymer, dispersed in an aqueous vehicle, which allows the medium to be readily “switched” between a non-gelatinous (fluid) form and a gelatinous form by simply adjusting temperature across the gelling temperature of the medium. As such, stem cells can be easily captured within a 3D gel matrix by simply mixing the stem cells with the non-gelatinous/fluid form of the medium and then gelling the medium by adjusting the temperature across the gelling temperature of the medium. The stem cells encapsulated within the gelatinous form of the medium may then be preserved for a significant time period before either using the stem cells directly within the medium (e.g. in therapy, or in culturing, differentiation, and such like), or after their extraction from the medium.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: December 11, 2018
    Assignee: The University of Sheffield
    Inventors: Irene Canton, Steven Peter Armes, Nicholas John Warren, Harry Moore, Giuseppe Battaglia, Denis Cecchin
  • Patent number: 10138463
    Abstract: The present invention relates to methods for production of undifferentiated or differentiated embryonic stem cell aggregate suspension cultures from undifferentiated or differentiated embryonic stem cell single cell suspensions and methods of differentiation thereof.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: November 27, 2018
    Assignee: VIACYTE, INC.
    Inventor: Thomas C Schulz
  • Patent number: 10106773
    Abstract: The present invention relates to methods of isolating a substantially homogeneous population of pluripotent stem cells from adult neural crest tissue (e.g., periodontal ligament) as well as pharmaceutical compositions comprising such isolated pluripotent stem cells. Methods of inducing the isolated pluripotent stem cells into specific cell lineages, such as neurogenic and retinogenic lineages, are also described. The isolated pluripotent stem cells find use in various regenerative medicine applications and the treatment of degenerative diseases.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: October 23, 2018
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Herman S. Cheung, Daniel Pelaez, C-Y Charles Huang
  • Patent number: 10064893
    Abstract: Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: September 4, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Christopher H. Contag, Stephen H. Thorne
  • Patent number: 10047341
    Abstract: Provided herein are methods for the generation of functional keratinocyte stem cells that are differentiated directly from human ESCs/iPSCs in a chemically defined serum-free cell culture system, as well as cells derived therefrom and methods of use thereof. Also provided are methods for culturing primary keratinocytes.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: August 14, 2018
    Assignee: FUJIFILM Cellular Dynamics, Inc.
    Inventors: Junying Yu, Ying Zhang, Lisa Harms
  • Patent number: 10035118
    Abstract: A system and method for isolating and separating lipoaspirate particles. The system includes a generally cylindrical container having a lid and a bottom wherein the container includes at least one input port positioned to permit a lipoaspirate fluid to enter the container above the bottom; and a source of a vacuum coupled to the container to provide a partial vacuum during use of the system.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: July 31, 2018
    Assignee: SpineSmith Partners, L.P.
    Inventors: Ted Sand, David Chau, Matthew R. DeWitt, Sujata Ghosh, Kevin Hao-Yu Lin
  • Patent number: 10030057
    Abstract: Described herein are novel compositions comprising multimodal TRAIL agents and cells engineered to express such multimodal TRAIL agents, including cells encapsulated in a scaffold or matrix, for use in the treatment of disorders such as cancer.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: July 24, 2018
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventor: Khalid Shah
  • Patent number: 10018630
    Abstract: An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: July 10, 2018
    Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, PHARMALOGICALS RESEARCH PTE. LTD.
    Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Atsuhiko Kato, Masami Suzuki
  • Patent number: 10018040
    Abstract: A technique facilitates detection and analysis of constituents, e.g. chemicals, which may be found in formation fluids and/or other types of fluids. The technique comprises intermittently introducing a first fluid and a second fluid into a channel in a manner which forms slugs of the first fluid separated by the second fluid. The intermittent fluids are flowed through the channel to create a mixing action which mixes the fluid in the slugs. The mixing increases the exchange, e.g. transfer, of the chemical constituent between the second fluid and the first fluid. The exchange aids in sensing an amount of the chemical or chemicals for analysis. In many applications, the intermittent introduction, mixing, and measuring can be performed in a subterranean environment.
    Type: Grant
    Filed: October 25, 2015
    Date of Patent: July 10, 2018
    Assignee: SCHLUMBERGER TECHNOLOGY CORPORATION
    Inventors: Farshid Mostowfi, Ronald E. G. van Hal, Shahnawaz Hossain Molla, Jane T. Lam, Amy Du, Neil William Bostrom, Michael Mallari Toribio
  • Patent number: 10010883
    Abstract: A deterministic lateral displacement array that includes a channel, within a substrate, having a first sidewall, a second sidewall, and a channel length. A condenser portion that includes an entry port and an exit port. A first array of pillars is disposed between the entry port and the exit port of the condenser portion along the channel length, the first array of pillars operative to drive a first material particle and a second material particle towards the first sidewall of the channel. A separator portion that includes an entry port and an exit port, and a second array of pillars disposed between the entry port and the exit port of the separator portion along the channel length, the pillars operative to drive the first material particle towards the second sidewall of the channel.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: July 3, 2018
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Huan Hu, Sung Cheol Kim, Joshua T. Smith, Benjamin H. Wunsch
  • Patent number: 10000740
    Abstract: This invention relates to the differentiation of pluripotent cells (PSCs) into foregut stem cells (FSCs) using a definitive endoderm induction medium comprising a TGFfi ligand, fibroblast growth factor (FGF), bone morphogenetic protein (BMP) and a PI3K inhibitor to differentiate the pluripotent cells into definitive endoderm cells and a foregut induction medium comprising a TGF? ligand to differentiate the definitive endoderm cells into foregut stem cells (FSCs). Methods of differentiation, populations of foregut stem cells, culture media and kits are provided.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: June 19, 2018
    Assignee: Cambridge Enterprise Limited
    Inventors: Ludovic Vallier, Nicholas Hannan
  • Patent number: 10000813
    Abstract: The invention relates to method and compositions for treating and diagnosing cancer, in particular ?-catenin related cancers. In general, the methods include administering RNAi constructs. The invention further relates to methods of identifying CTNNB1 related cancer therapeutics.
    Type: Grant
    Filed: January 3, 2012
    Date of Patent: June 19, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Mark J. Roth, Konrad Huppi
  • Patent number: 9994849
    Abstract: Provided is a method of separating senescent cells from a sample including the senescent cells, and a method of removing senescent cells from a sample or a subject including the senescent cells.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: June 12, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Byungju Kim, Sungjin Ryu, Sangchul Park
  • Patent number: 9994810
    Abstract: The present invention relates to an a process for manufacturing dry powder cell culture media. The preparation and usage of mixed particles generated by co-lyophilisation leads to homogenously blended cell culture media.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: June 12, 2018
    Assignee: MERCK PATENT GMBH
    Inventor: Joerg Von Hagen
  • Patent number: 9994812
    Abstract: The present invention generally relates to the field of cell growth and tissue engineering, in particular, tissue engineered compositions comprising a nanotextured substrate which is structurally configured for growth of cells in an anatomically correct adult phenotype in vitro. In particular, described herein are nanotextured substrates which are structurally configured for the anisotropic organization, maturation, and growth of in vitro-differentiated muscle cells, such as cardiomyocytes, and methods for the production and use thereof in varying sizes, nanotextures and substrate rigidities. In vitro-differentiated cardiomyocytes grown on the nanotextured substrates described herein are better-differentiated and more closely mimic adult cardiac tissue than the same cells grown on a non-textured substrate of the same composition.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 12, 2018
    Assignee: University of Washington through Its Center For Commercialization
    Inventors: Deok-Ho Kim, Michael Laflamme, Charles Murry, Kshitiz Gupta, Hyok Yoo, Alex Jiao
  • Patent number: 9994822
    Abstract: This invention provides a method for testing a factor for cardiogenicity which comprises differentiating human embryonic stem (hES) cells to cardiomyocytes in the presence and absence of the factor wherein the human embryonic stem (hES) cells are cultured under a serum free condition comprising co-culture in the presence of END-2 cells or serum-free extracellular medium therefrom, and measuring the differentiation in the presence and absence of the factor. This invention also provides a method for identifying a cardiogenic factor, which comprises differentiating human embryonic stem (hES) cells to cardiomyocytes in the presence or absence of the factor wherein the human embryonic stem (hES) cells are cultured under a serum free condition comprising co-culture in the presence of END-2 cells or serum-free extracellular medium therefrom, and identifying the factor that affects the differentiation of human embryonic stem (hES) cells to cardiomyocytes in the presence or absence of the factor.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: June 12, 2018
    Assignee: ES Cell International Pte Ltd
    Inventors: Robert Passier, Christine L. Mummery
  • Patent number: 9988606
    Abstract: Embodiments of the present invention are directed to various methods for generating airway and lung progenitors and epithelial cells and three-dimensional anterior foregut spheres, and to populations of cells made using the methods. The airway and lung progenitors and epithelial cells can be used as a model to study diseases that primarily affect airway epithelial cells, and to study human lung development. Methods are also provided for drug screening. Anterior foregut spheres can be used as a model for lung fibrosis.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: June 5, 2018
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Hans-Willem Snoeck, Sarah Xuelian Huang, Ya-Wen Chen, Jahar Bhattacharya, Mohammad Naeem Islam
  • Patent number: 9988605
    Abstract: The present invention prepared insulin-producing endocrine cells by inducing the differentiation of human embryonic stem cells or human induced pluripotent stem cells into definitive endoderm (DE), pancreatic endoderm (PE), endocrine progenitors (EP), and endocrine cells (EC) stepwise in that order. Particularly, the present invention established the conditions for the formation of an insulin producing endocrine aggregate (EA) from the endocrine cells. Especially in this invention, it was confirmed that the endocrine aggregate has the cell proliferation potential at a significant level and has the increased insulin productivity as well as the activity of inhibiting cell necrosis and apoptosis. Therefore, the method for preparing the endocrine aggregate of insulin-producing beta cells from human pluripotent stem cells can be effectively used for the examination of the medicinal effect of the conventional antidiabetic agents and of the novel antidiabetic drugs.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: June 5, 2018
    Assignee: Korea Advanced Institute of Science and Technology
    Inventors: Yong-mahn Han, Young-jin Kim, Hail Kim
  • Patent number: 9982231
    Abstract: Compositions and methods are described herein for chemically inducing cells to change their differentiation state and become cardiac progenitor cells or cardiomyocytes.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: May 29, 2018
    Assignee: THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE
    Inventors: Nan Cao, Sheng Ding
  • Patent number: 9982233
    Abstract: The present invention relates to a method of promoting generation of exosomes from stem cell by using thrombin. The method according to the present invention has superior effects of promoting generation of stem cell-derived exosomes and thus exosomes can be more efficiently obtained thereby compared to conventionally known methods. In addition, the method can be useful for related research.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: May 29, 2018
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Yun Sil Chang, Won Soon Park, Dong Kyung Sung, So Yoon Ahn
  • Patent number: 9969982
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells and the products related to or resulting from such methods. In particular, the present invention provides an improved method for the formation of pancreatic hormone expressing cells and pancreatic hormone secreting cells. In addition, the present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer and the products related to or resulting from such methods. The present invention also provides methods to promote glucose-stimulated insulin secretion in insulin-producing cells derived from pluripotent stem cells.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: May 15, 2018
    Assignee: LifeScan, Inc.
    Inventor: Alireza Rezania
  • Patent number: 9963679
    Abstract: Methods of preparing pancreatic islets that may comprise pancreatites are provided. The methods may involve subjecting a pancreas and/or pieces thereof to disruption, such as, for example, an enzyme digest, and seeding the recovered cellular product comprising islets in a culture medium comprising at least a detectable amount of endocrine tissue and/or exocrine tissue.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: May 8, 2018
    Assignee: LIFELINE SCIENTIFIC, INC.
    Inventors: Michael J. Taylor, Simona C. Baicu
  • Patent number: 9950095
    Abstract: The invention provides a method for producing an implant from interstitial, connective or supporting tissue, the method comprising at least one step of perfusing the tissue with at least one decellularization medium under negative pressure applied for substantially the whole time period of the perfusion.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: April 24, 2018
    Assignee: Videregen Limited
    Inventors: Tahera Iqbal Ansari, Paul David Sibbons
  • Patent number: 9944901
    Abstract: Provided is a protein coded by a gene related to cell totipotency and a transcriptional activation domain of a mammalian YAP protein or a fusion protein of a segment with a transcriptional control activity, a coding nucleotide sequence, an expression vector and a composition thereof, as well as a method for inducing the pluripotent stem cells by using the fusion protein.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: April 17, 2018
    Assignees: Institute of Zoology, Chinese Academy of Sciences, Emory University School of Medicine
    Inventors: Dahua Chen, Peng Jin, Qinmiao Sun, Weiqi Tan
  • Patent number: 9938500
    Abstract: Methods of generating and expanding human hemangio-colony forming cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: April 10, 2018
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Robert Lanza, Shi-Jiang Lu
  • Patent number: 9932556
    Abstract: The present invention relates to a method for in vitro differentiation of a population of blood circulating cells, such as monocytes and preferably pluripotent macrophages derived therefrom, into cells displaying functional and phenotypic neuronal characteristics. The invention further encompasses neuronal-like cells obtainable according to the present method, compositions comprising said cells, and applications thereof.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: April 3, 2018
    Assignees: Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes, Institut Ntaitonal de la Sante et de la recherche Medicale (INSERM), Assistance Publique—Hopitaux de Paris
    Inventors: Anne Hosmalin, Vincent Feuillet, Marie-Odile Krebs, Thérèse Jay, Alfredo Bellon
  • Patent number: 9920299
    Abstract: Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: March 20, 2018
    Assignee: International Stem Cell Corporation
    Inventors: Elena S. Revazova, Leonid N. Kuzmichev, Nickolay A. Turovets, Jeffrey D. Janus
  • Patent number: 9903796
    Abstract: A photocleavable polymer comprising a photocleavable linker and a polymer having a functional group that binds to a protein, lipid, sugar of a cell, or any combination thereof, as well as a method of selectively lysing cells by incubating a sample comprising two or more cells with the photocleavable polymer to reversibly fix the cells; selectively irradiating the fixed cells or a target or non-target cell among the fixed cells to cleave the photocleavable polymer; and adding a cell lysis solution to selectively lyse the irradiated cells.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: February 27, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hun-joo Lee, Yeon-jeong Kim, Dong-hyun Park, Jong-myeon Park
  • Patent number: 9884076
    Abstract: The present disclosure relates generally to methods for the increased processing of tissue for the generation of cardiac stem cells, wherein the stem cells are suitable for use in cardiac stem cell therapy. In particular, several embodiments relate to the processing of allogeneic donor cardiac tissue for the generation of multiple patient doses of cardiac stem cells.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: February 6, 2018
    Assignee: Capricor, Inc.
    Inventors: Michelle Kreke, Rachel Smith
  • Patent number: 9868936
    Abstract: The present invention is directed towards methods for producing cell and tissue compositions suitable for therapeutic applications to a mammal in need of a therapeutic cell or tissue treatment. In particular, the invention is directed towards a method of culturing cells for use in therapy, which method comprises (i) culturing a sample of cells in a first cell culture medium and (ii) prior to harvesting cells for use in therapy culturing the cells in a second cell culture medium.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: January 16, 2018
    Assignee: ISOPOGEN PTY LTD
    Inventor: Marian June Sturm
  • Patent number: 9856293
    Abstract: A synthetic peptide having nestin expression inducing ability which allows induction of expression of nestin in astrocytes; an agent for inducing nestin expression including the peptide as an active ingredient; and a method for producing high nestin expressing cells derived from astrocytes, the method being characterized in that the agent for inducing nestin expression is supplied. The agent for inducing nestin expression provided by the present invention includes, as an active ingredient, a synthetic peptide including a nestin-inducing peptide sequence consisting of an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence formed by conservative replacement of 1, 2 or 3 amino acid residues in the amino acid sequence. The method for producing high nestin expressing cells derived from astrocytes provided by the present invention includes preparing an astrocyte culture, and supplying, at least once, the agent for inducing nestin expression to the astrocyte culture.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: January 2, 2018
    Assignee: TOAGOSEI CO. LTD.
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida
  • Patent number: 9844514
    Abstract: This application discloses methods for treating an established myocardial infarction, including treatment with an epicardial construct containing stromal vascular fraction (SVF) from adipose tissue which may be seeded onto a biocompatible substrate, which preserves microvascular function and LV contractile mechanisms.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: December 19, 2017
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Stuart K. Williams, James B. Hoying, Amanda J. LeBlanc
  • Patent number: 9845460
    Abstract: The present invention is provides a method for treating human pluripotent cells. In particular, the methods of the invention are directed to the treatment of human pluripotent cells, whereby the human pluripotent cells can be efficiently expanded in culture and differentiated by treating the pluripotent cells with an inhibitor of glycogen synthase kinase 3? (GSK-3B) enzyme activity.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: December 19, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Janet Davis, Jiajian Liu
  • Patent number: 9822343
    Abstract: This document provides methods and materials involved obtaining induced pluripotent stem (iPS) cells. For example, methods and materials for increasing the efficiency for making iPS cells as well as methods and materials for selecting iPS cells are provided.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: November 21, 2017
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Timothy J. Nelson, Andre Terzic, Almudena J. Martinez Fernandez, Clifford D. Folmes
  • Patent number: 9790469
    Abstract: The subject matter of the invention is a functional population of human brown adipocytes, in which the expression of UCP1, CIDEA, CPT1B and Bc12 is higher, the expression of Bax is lower and the expression of PPAR-alpha, PGC-1alpha, PGC-1 beta and PRDM16 is similar compared with the corresponding expressions of a population of human white adipocytes. The invention also relates to a method for differentiation of hMADS cells into the functional population of human brown adipocytes, to a method for conversion of a population of human white adipocytes into the functional population of human brown adipocytes, and also to a method of screening for molecules capable of modulating the bodyweight in an individual.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: October 17, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE NICE SOPHIA-ANTIPOLIS
    Inventors: Gérard Paul Ailhaud, Ez-Zoubir Amri, Christian Jean Lucien Dani, Christian Elabd
  • Patent number: 9783784
    Abstract: In some embodiments, methods for improving the survival of pancreatic ?-cell progenitors in culture are provided. Such methods may include contacting a population of pancreatic progenitor cells with an amino acid (aa) sequence comprising IKVAV (SEQ ID NO:1). In other embodiments, methods for (i) verifying the establishment of a population of pancreatic progenitor or stem cells and (ii) methods for generating or establishing a population of pancreatic endocrine progenitor cells in vitro are provided.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 10, 2017
    Assignees: CITY OF HOPE, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Hsun Ku, David Tirrell
  • Patent number: 9770473
    Abstract: Disclosed are methods of using blastomere-like stem cells to decrease a level of myeloid-derived suppressor cells (MDSCs). A method for decreasing a level of myeloid-derived suppressor cells (MDSCs) in a human subject, including: injectionally, orally or transdermally administering to the human subject an amount of human blastomere-like stem cells, autologous to the human subject, at 1×108 to 1×1011 cells each time once every two weeks, for example.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: September 26, 2017
    Assignee: StemBios Technologies, Inc.
    Inventors: James Wang, Yun Yen, Lufen Chang
  • Patent number: 9764516
    Abstract: A method of making an organ or tissue comprises: (a) providing a first dispenser containing a structural support polymer and a second dispenser containing a live cell-containing composition; (b) depositing a layer on said support from said first and second dispenser, said layer comprising a structural support polymer and said cell-containing composition; and then (c) iteratively repeating said depositing step a plurality of times to form a plurality of layers one on another, with separate and discrete regions in each of said layers comprising one or the other of said support polymer or said cell-containing composition, to thereby produce provide a composite three dimensional structure containing both structural support regions and cell-containing regions. Apparatus for carrying out the method and composite products produced by the method are also described.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: September 19, 2017
    Assignee: Wake Forest University Health Sciences
    Inventors: Hyun-Wook Kang, Sang Jin Lee, Anthony Atala, James J. Yoo
  • Patent number: 9732318
    Abstract: This disclosure relates to compositions comprising human preprimitive streak cells and/or human mesendoderm cells as well as methods for their production. Additionally, disclosed herein are methods of identifying factors useful in the further differentiation of preprimitive streak and mesendoderm cell types.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: August 15, 2017
    Assignee: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazar, Evert Kroon, Emmanuel E. Baetge
  • Patent number: 9725699
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: August 8, 2017
    Assignee: LifeScan, Inc.
    Inventors: Alireza Rezania, Jean Xu
  • Patent number: 9714280
    Abstract: Disclosed herein are genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: July 25, 2017
    Assignee: ESCAPE THERAPEUTICS, INC.
    Inventor: Basil M. Hantash
  • Patent number: 9708582
    Abstract: The present disclosure provides methods of generating germ layers from stem cells comprising culturing the stem cells in a culture media having osmolality ranges that promote the generation of specific germ layer progenitor cells. The present disclosure also includes a method to generate different cell lineages from the germ layers as well as to detect them by immunological methods. The present disclosure further provides methods for the generation, isolation, cultivation and propagation of committed progenitor cells and for the production of differentiated cells from the three germ layers. The present disclosure also provides culture media and kits for use in inducing the three germ layers.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: July 18, 2017
    Assignee: Stemcell Technologies Inc.
    Inventors: Alexandra A. Blak, Sharon A. Louis, Michael John Riedel
  • Patent number: 9695445
    Abstract: An objective of the present invention is to provide vectors for conveniently and efficiently producing ES-like cells in which foreign genes are not integrated into the chromosome. The present inventors discovered methods for producing ES-like cells from somatic cells using chromosomally non-integrating viral vectors. Since no foreign gene is integrated into the chromosome of the produced ES-like cells, they are advantageous in tests and research, and immunological rejection and ethical problems can be avoided in disease treatments.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: July 4, 2017
    Assignee: ID Pharma Co., Ltd.
    Inventors: Noemi Fusaki, Hiroshi Ban, Mamoru Hasegawa, Yoshikazu Yonemitsu